Лучшие в мире врачи

Контент соответствует редакционной политике Bookimed и его качество проверил

Фахад Мавлюд - Врач общей практики, лауреат 4 конкурсов научных работ молодых ученых. Работал на Среднем Востоке. Бывший руководитель команды англоязычных и арабоязычных врачей-координаторов. Сейчас занимается анализом данных и выступает медицинским редактором сайта.

Dr Murat Ayhan

36 лет опыта

5.0

7 отзывов

Turkey, Istanbul

Liv Hospital Vadistanbul

Dr Murat Ayhan

36 лет опыта

Areas of Interests

Breast cancer
Lung cancer
Colorectal cancers
Gynecological and urogenital cancers
Molecular Oncology

Education:

Kızıltepe Anatolian High School 2001
Dicle University Faculty of Medicine 2007
Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
Kartal City Hospital 2021
Associate Professor of Medical Oncology 2023

Experience:

Liv Hospital Ulus
Adıyaman University Training and Research Hospital
Istanbul Umraniye Training and Research Hospital
Istanbul Umraniye Training and Research Hospital

Research:

Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
Publications:
Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
Book Writing:
Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Читать подробнее

Areas of Interests

Breast cancer
Lung cancer
Colorectal cancers
Gynecological and urogenital cancers
Molecular Oncology

Education:

Kızıltepe Anatolian High School 2001
Dicle University Faculty of Medicine 2007
Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
Kartal City Hospital 2021
Associate Professor of Medical Oncology 2023

Experience:

Liv Hospital Ulus
Adıyaman University Training and Research Hospital
Istanbul Umraniye Training and Research Hospital
Istanbul Umraniye Training and Research Hospital

Research:

Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
Publications:
Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
Book Writing:
Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Читать подробнее

5.0

7 отзывов

Получить бесплатную консультацию Информация

Meltem Topalgokceli Selam

28 лет опыта

4.5

235 отзывов

Turkey, Istanbul

Liv Hospital Ulus

Meltem Topalgokceli Selam

28 лет опыта

The doctor specializes in medical oncology with a focus on gastrointestinal and ovary cancers. With extensive experience working at the Department of Medical Oncology at Liv Hospital and the Oncology Institute at Istanbul Faculty of Medicine, the doctor has contributed significantly to the field. The doctor is a member of the Turkish Medical Oncology Society and the Istanbul Breast Cancer Research Group.

The doctor has authored 3 international and 9 national publications, along with 7 reports presented at national scientific meetings. The doctor completed medical education at Istanbul Faculty of Medicine and has been involved in manual translation work.

Читать подробнее

4.5

235 отзывов

Получить бесплатную консультацию Информация

Nasuh Kolsuz

16 лет опыта

5.0

5 отзывов

Nasuh Kolsuz

16 лет опыта

Turkey, Antalya

Renova Style Clinic

5.0

5 отзывов

Получить бесплатную консультацию Информация

Alper Karalok

15 лет опыта

4.5

235 отзывов

Turkey, Istanbul

Liv Hospital Ulus

Alper Karalok

15 лет опыта

The doctor graduated from Ankara University Medical Faculty in 2004 and specialized in obstetrics and gynecology at Akdeniz University by 2011. Further honing expertise in gynecologic oncology, the doctor completed a sub-specialization at Etlik Zübeyde Hanım Hospital in 2014 and observed robotic surgery at Memorial Sloan Kettering Cancer Center in 2018. The clinical focus includes pinhole surgery in gynecologic cancers, pre-invasive cervical lesions, and ovary cancer surgery. With extensive experience at Liv Hospital Ulus and Etlik Zübeyde Hanım Hospital, the doctor is also a member of ESGO and ENYGO.

Читать подробнее

4.5

235 отзывов

Получить бесплатную консультацию Информация

Omer Buhsem

32 года опыта

5.0

8 отзывов

Turkey, Bursa

Estetik International Bursa

Omer Buhsem

32 года опыта

Educations

Adana AnadoluCollege ( 1978-1985)

Medical School : UludagUniversityMedicalSchoolBursa (1985-1991)

Plastic Surgery Education: UludagUniversityMedical School Bursa (1994-2000)

Academic and Porfessional Appointments and societies :

Turkish Board Certified Plastic Reconstructive and Aesthetic Surgeon

Chief, Division of Plastic &Reconstructive Surgery Dicle University School of Medicine, Assistant Professor(2008)

Founding President of Facial Aesthetic Surgery and Rhinoplasty Society (EYBCD) 2009

TPRCD Turkısh Society of Plastic Reconstructive an Aesthetic Surgery (member of board of directory 2008)

EPCD Turkish Society of Aesthetic Plastic Surgery (reserve member of board of directory 2009)

Director and surgeon general of Acibadem Konur Medical Center ( 2009-2012)

ESPRAS European Society of Plastic Reconstructive and Aesthetic Surgery (member)

ISAPS The International Society of Plastic Surgery Society member

ASAPS The American Society for Aesthetic Plastic Surgery member

European Comittee For Standardisation Mirror Committee member

Experiences in Surgery: ( over 9000 surgery between 2000-2019)

Aesthetic Surgery

PlasticandReconstructiveSurgery

Hand and Microsurgery

Maxillofacial Surgery

Publications, posters and presentations

Extensor Carpi Ulnaris Dislocation Due To Sixth Compartment Rupture

Ömer Buhşem, Ahmet Karacalar, MesutÖzcan

Journal of Turkish Plastic, Reconstructive and Aesthetic Surgery, Cilt 7, Sayı 3 (1999)

Nasal Dermoid Sinus Cyst

Ömer Buhşem, Ahmet Karacalar

Journal of Turkish Plastic, Reconstructive and Aesthetic Surgery, Cilt 8, Sayı 2 (2000)

Retrospective Evaluation of Cleft Lip and Palate Patients Underwent Surgery In DUTF between Oct. 1987- Nov. 1999

Ömer Buhşem, Kemal Erbaş,İbrahim Aşkar

22. Turkısh Society of Plastic Reconstructive an Aesthetic Surgery Congress (2000)

Lineer Verrucosis epidermal nevus including Cornu Cutanu : casereport

İ.Aşkar, S.Aktürk, Ömer Buhşem ,H. Büyükbayram K. Erbaş,

22.Turkish Society of Plastic Reconstructive an Aesthetic Surgery Congress (2000)

Evaluation of the effects of 5-Fluorouracil application following Ratsciatic nerve repair on epineural

and extraneural scarring and nerveregeneration.

Ömer Buhşem, Yeşim Özgenel, Mesut Özcan

23. Turkish Society of Plastic Reconstructive an Aesthetic Surgery Congress (27-30 sept. 2001)

Minimal Invasive Procedures in Rhinoplasty (no osteotomy rhinoplasty)

TPRECD Rhinoplasty Winter Symposium (2007)Bursa

Laser hair removal procedures

European Academy of Cosmetic Surgery International Workshop Symposium İstanbul 2007

Tripollar Radiofrequency

European Academy of Cosmetic Surgery International Workshop Symposium İstanbul 2007

Focused Ultrasonic Fat Emulsification

European Academy of Cosmetic Surgery International Workshop Symposium İstanbul 2007

“ Latest development tendencies concerning face and body RF therapy”

7. International Congress on Aesthetic Medicine 2008 Moscow

No osteotomy rhinoplasty

Turkish – Azerbajian Plastic Surgery Days (2008) Bakü-Azerbajian

Tripollar RF treatments for circumference reduction and non-surgical face lift

European Academy of Dermatology and Venereology 5th EADVSpring Symposium (2008) İstanbul

Mini Rhinoplasty (no osteotomy rhinoplasty)

XXI.SOFCEPSociétéFrançaise desChirurgiensEsthétiquesPlasticiens,Euro-MéditerranéenCongrés(2008 ) France - Paris

Tripollar RF technology for nonsurgical skin tightening and cellulite treatment

VI.İnternational Plastic Surgery Course I. International Anti-Aging Symposium (2008) Ekaterinburg- Russia

New Medlite technology Photo-Acoustic Pulse therapy

Aesthetic Plastic Surgery Society 12th National Congress Minimal Invasive Surgery Course (2008) İstanbul

A new vaginal stent material:Alginate

22. Turkish Society of Plastic Reconstructive an Aesthetic Surgery Congress (2008)Antalya

No osteotomy rhinoplasty : Algoritm

22. Turkish Society of Plastic Reconstructive an Aesthetic Surgery Congress (2008)Antalya

Axillar Brachial Plexus Blockage by Plasticsurgeons

23. Turkish Society of Plastic Reconstructive an Aesthetic Surgery Congress (2008)Antalya

TriPollar RF Non-Surgical Face Lift & Skin Tightening - Long Term Results

White paper 2008

My approach to aesthetic rhinoplasty

Facial Aesthetic Surgery and Rhinoplasty Society Rhinoplasty days (2009) Istanbul

No Osteotomy Rhinoplasty

Facial Aesthetic Surgery and Rhinoplasty Society Rhinoplasty days (2009) Istanbul

Laser Treatments in facialrejuvenations

TPRECD Winter symposium ( 2010) Bolu Kartalkaya

Non irritatingAHA treatments inDermatology

TPRECD Winter symposium ( 2010) Bolu Kartalkaya

Non invasive weight loss with low level diode laser

Turkish Society of Plastic Reconstructive an Aesthetic Surgery Winter symposium (2011) Uludag

Mini rhinoplasty (rhinoplasty without osteotomy)

Aesthetic Plastic Surgery Society National Congress (2012) Istanbul

Mini Rhinoplasty (no osteotomy rhinoplasty)

5th EASAPS The European Association of Societies of Aesthetic Plastic Surgery Meeting (2012) Istanbul

Minimal invasive rhinoplasty (mini rhinoplasty)

TPRECD V. Rhinoplasty course (2012) Ankara

Mini Rhinoplasty (no osteotomy rhinoplasty)

Seoul Rhinoplasty Forum ( 2012) Seoul South Korea

No osteotomy rhinoplasty ( desicion of osteotomy)

TPRECD II Istanbul International Rhinoplasty Course (2013) Istanbul

Columelar surgery and softrhinoplasty

TPRECD VII. Rhinoplasty course (2014) Izmir

Increasing Topical Anesthetic Efficacy with MicroneedleApplication

Ömer Buhsem, Alper Aksoy, Yavuz Kececi, Emin Sir & Melike Güngör (2016)

Journal of Cosmetic and Laser Therapy, DOI: 10.3109/14764172.2016.1157362

Skin Resurfacing

Grabb and Smith Plastik Cerrahi 7. Baskı Kısım 5, 41 Türkçe çeviri (2016)

Organic Dermal implant revolution: new molecule introduction

Kuwait Derma Update and Laser Symposium VIII, Kuwait (2017)

Natural injectable implant : agarose gel

The 12.th International Conference of Aesthetic and Antiaging Medicine Warsaw Poland (2017)

Facial Applications with Radiofrequency Energy, Review

Journal Türkiye Klinikleri Plastik Cerrahi Cilt:7, Sayı:1 (2018)

Nonsurgical Rhinoplasty with Agarose gel

International Medical Aesthetic Conference Kuala Lumpur, Malaysia (2018)

Agarose gel : a natural injectable implant and volumizer

Dubai Derma World Dermatology and Laser Conference Dubai (2018)

Dermal fillers (DAS)

TPRECD 40. Ulusal Kurultayı Antalya (2018)

Botilinum toksin ve dolgu uygulamaları

Plastik Cerrahi Asistan Okulu, Antalya (2019)

Filler Complications and Management

23. Ulusal Estetik Plastik Cerrahi Kongresi İstanbul (2019)

Midface and zygoma volumizing with agarose gel

SIES International Aesthetic Medicine and Surgery Congress Bologna Italy (2019)